Breaking News Instant updates and real-time market news.

MGNX

MacroGenics

$11.04

-0.34 (-2.99%)

07:23
10/23/19
10/23
07:23
10/23/19
07:23

MacroGenics price target lowered to $14 from $23 at Wedbush

Wedbush analyst David Nierengarten lowered his price target for MacroGenics to $14 from $23 following a worse-than-expected readout of the second interim OS analysis, prompted at 270 events, from the pivotal Phase 3 SOPHIA trial evaluating margetuximab and chemo against trastuzumab and chemo in patients with 3/4L HER2+ metastatic breast cancer. The analyst believes that "perhaps the most concerning read from the update" is the deterioration of margetuximab's relative benefit over trastuzumab in the CD16A 158F allele population, which saw a relative OS benefit of 6.7 months at the first interim analysis drop to 4.3 months at the second, largely due to better-than-expected survival in the trastuzumab arm. Nierengarten has an Outperform rating on the shares.

  • 06

    Nov

MGNX MacroGenics
$11.04

-0.34 (-2.99%)

05/16/19
FBCO
05/16/19
NO CHANGE
Target $29
FBCO
Outperform
MacroGenics SOPHIA abstract leaves more questions than answers, says Credit Suisse
Commenting on MacroGenics' Phase 3 SOPHIA trial, Credit Suisse analyst Michael Morabito says that physician experts with whom he has been consulting were hoping for a benefit of at least 2 months compared to Herceptin, which they would consider practice changing in this third-line setting of patients who progressed on Herceptin/Perjeta/Kadcyla. With the net benefit for margetuximab coming in at only 0.9 months, the analyst would expect the shares could see increased pressure on this data. He reiterates an Outperform rating and $29 price target on the shares.
06/04/19
STFL
06/04/19
NO CHANGE
STFL
Stifel 'gut reaction' to margetuximab data aligns with 19% selloff
Stifel analyst Stephen Willey says his "gut reaction" to today's more-detailed Sophia data appears to align with how the stock is trading post this morning's presentation. Shares of MacroGenics are down 19%, or $3.55, to $15.17 in midday trading. The analyst found the overall survival data of margetuximab the most disappointing. He had hoped the large absolute median OS benefit in low-affinity CD16A-158 patients favoring margetuximab would offset some of the concern around the clinical relevance of the progression free survival benefit. Unfortunately, however, this benefit appears to be less compelling when viewed in the context of the full Kaplan-Meier curve, Willey tells investors in a research note titled "First Take on SOPHIA Data Presentation - Don't Expect OS to Pick Up the PFS Slack." The analyst continues to believe the Sophia data represents an approvable data set, but he admits the addressable market opportunity is "likely now amplified following today's presentation." The continued perception of margetuximab as an overhang could serve to keep near-term enthusiasm in MacroGenics shares "muted," says Willey. He keeps a Buy rating on the shares.
06/05/19
STFL
06/05/19
NO CHANGE
Target $29
STFL
Buy
MacroGenics price target lowered to $29 from $36 at Stifel
Stephen analyst Kevin Willey lowered his price target for MacroGenics to $29 from $36, saying he expects maturing overall survival data from Sophia to command "meaningful" regulatory and commercial importance given what is likely to remain perceived to be a progression free survival benefit of uncertain clinical relevance. Willey tells investors in a research note that he is now less optimistic directionally-supportive OS data will manifest over time in the intent-to-treat patient population and has "minimal" confidence the early numerical OS separation favoring margetuximab in CD16A-158F patients will prove durable. He maintains a Buy rating.
07/18/19
HCWC
07/18/19
NO CHANGE
Target $39
HCWC
Buy
H.C. Wainwright sees 'nothing sinister' with MacroGenics regaining drug rights
H.C. Wainwright analyst Debjit Chattopadhyay sees nothing "inherently sinister" with flotetuzumab after MacroGenics regained the full rights to the drug. After speaking with management, the analyst says that ex-partner Servier was not been particularly engaged during the development process and that to date, MacroGenics has been funding both the U.S. and European studies. Further, flotetuzumab's emerging clinical profile remains consistent with what was presented at ASH 2018, and an updated presentation on the fully enrolled dose expansion cohort is expected at ASH 2019, Chattopadhyay tells investors in a research note. He keeps a Buy rating on MacroGenics shares with a $39 price target.

TODAY'S FREE FLY STORIES

KKR

KKR

$29.68

0.3 (1.02%)

, DIS

Disney

$147.85

-0.84 (-0.56%)

12:09
11/14/19
11/14
12:09
11/14/19
12:09
Hot Stocks
'Fortnite' streamer Ewok moving to Microsoft's Mixer from Amazon's Twitch »

Soleil "Ewok"…

KKR

KKR

$29.68

0.3 (1.02%)

DIS

Disney

$147.85

-0.84 (-0.56%)

TCEHY

Tencent

$0.00

(0.00%)

MSFT

Microsoft

$147.39

0.06 (0.04%)

AMZN

Amazon.com

$1,751.40

-2.44 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 19

    Nov

  • 20

    Nov

  • 04

    Dec

  • 09

    Dec

MRTX

Mirati Therapeutics

$102.34

1.6 (1.59%)

12:05
11/14/19
11/14
12:05
11/14/19
12:05
Options
Mirati Therapeutics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:05
11/14/19
11/14
12:05
11/14/19
12:05
General news
The Treasury's $95 B 4- and 8-week bill offerings were mixed »

The Treasury's $95 B…

12:05
11/14/19
11/14
12:05
11/14/19
12:05
General news
Breaking General news story  »

St. Louis Federal Reserve…

12:05
11/14/19
11/14
12:05
11/14/19
12:05
General news
Breaking General news story  »

St. Louis Federal Reserve…

WMT

Walmart

$119.87

-1.19 (-0.98%)

, CSCO

Cisco

$44.69

-3.75 (-7.74%)

12:04
11/14/19
11/14
12:04
11/14/19
12:04
On The Fly
Fly Intel: Wall Street's top stories at midday »

The Dow and S&P…

WMT

Walmart

$119.87

-1.19 (-0.98%)

CSCO

Cisco

$44.69

-3.75 (-7.74%)

AXNX

Axonics

$29.70

4.21 (16.52%)

DDS

Dillard's

$76.51

8.71 (12.85%)

NTAP

NetApp

$62.17

2.13 (3.55%)

RBBN

Ribbon Communications

$3.18

-0.87 (-21.48%)

CGC

Canopy Growth

$15.58

-2.94 (-15.87%)

WB

Weibo

$44.80

-8.01 (-15.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 09

    Dec

  • 10

    Dec

  • 12

    Dec

  • 12

    Feb

CGC

Canopy Growth

$15.64

-2.88 (-15.55%)

12:00
11/14/19
11/14
12:00
11/14/19
12:00
Hot Stocks
Canopy Growth falls -15.6% »

Canopy Growth is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 19

    Nov

I

Intelsat

$12.10

-2.31 (-16.03%)

12:00
11/14/19
11/14
12:00
11/14/19
12:00
Hot Stocks
Intelsat falls -16.0% »

Intelsat is down -16.0%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

CTRA

Contura Energy

$10.25

-7.9 (-43.53%)

12:00
11/14/19
11/14
12:00
11/14/19
12:00
Hot Stocks
Contura Energy falls -44.1% »

Contura Energy is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

GFF

Griffon

$24.95

3.23 (14.87%)

12:00
11/14/19
11/14
12:00
11/14/19
12:00
Hot Stocks
Griffon rises 14.2% »

Griffon is up 14.2%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PING

Ping Identity

$18.90

2.4 (14.55%)

12:00
11/14/19
11/14
12:00
11/14/19
12:00
Hot Stocks
Ping Identity rises 14.5% »

Ping Identity is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

IGT

International Game

$15.31

2.39 (18.50%)

12:00
11/14/19
11/14
12:00
11/14/19
12:00
Hot Stocks
International Game rises 18.8% »

International Game is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

11:55
11/14/19
11/14
11:55
11/14/19
11:55
General news
Powell assured the Fed will use its tools "aggressively" if appropriate »

Powell assured the Fed…

ACN

Accenture

$194.94

0.43 (0.22%)

11:52
11/14/19
11/14
11:52
11/14/19
11:52
Hot Stocks
Accenture announces intent to acquire consulting firm Silveo »

Accenture has announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Dec

VOD

Vodafone

$20.50

-0.61 (-2.89%)

11:45
11/14/19
11/14
11:45
11/14/19
11:45
Options
Vodafone call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:45
11/14/19
11/14
11:45
11/14/19
11:45
General news
Breaking General news story  »

New York Federal Reserve…

11:38
11/14/19
11/14
11:38
11/14/19
11:38
General news
4-Week Bill Auction Total Amount data reported »

4-Week Bill Auction Total…

11:38
11/14/19
11/14
11:38
11/14/19
11:38
General news
8-Week Bill Auction Total Amount data reported »

8-Week Bill Auction Total…

TMO

Thermo Fisher

$298.18

-1.72 (-0.57%)

, QGEN

Qiagen

$36.88

1.36 (3.83%)

11:37
11/14/19
11/14
11:37
11/14/19
11:37
Upgrade
Thermo Fisher, Qiagen rating change  »

Evercore upgrades Qiagen…

TMO

Thermo Fisher

$298.18

-1.72 (-0.57%)

QGEN

Qiagen

$36.88

1.36 (3.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 07

    Dec

WORK

Slack Technologies

$21.18

-0.12 (-0.56%)

11:35
11/14/19
11/14
11:35
11/14/19
11:35
Options
Slack put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

11:35
11/14/19
11/14
11:35
11/14/19
11:35
General news
Chair Powell said modern monetary theory (MMT) "is just wrong," »

Chair Powell said modern…

QGEN

Qiagen

$36.81

1.29 (3.63%)

11:32
11/14/19
11/14
11:32
11/14/19
11:32
Upgrade
Qiagen rating change  »

Qiagen upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

11:30
11/14/19
11/14
11:30
11/14/19
11:30
General news
Breaking General news story  »

San Francisco Federal…

11:30
11/14/19
11/14
11:30
11/14/19
11:30
General news
Breaking General news story  »

San Francisco Federal…

VREOF

Vireo Health

$0.00

(0.00%)

, CGC

Canopy Growth

$15.28

-3.24 (-17.49%)

11:28
11/14/19
11/14
11:28
11/14/19
11:28
On The Fly
Rising High: An exclusive talk with multi-state cannabis company Vireo Health »

In this edition of…

VREOF

Vireo Health

$0.00

(0.00%)

CGC

Canopy Growth

$15.28

-3.24 (-17.49%)

APHA

Aphria

$4.14

-0.32 (-7.17%)

ACB

Aurora Cannabis

$3.17

-0.37 (-10.45%)

CVSI

CV Sciences

$0.00

(0.00%)

CTST

CannTrust

$0.92

-0.0569 (-5.85%)

CRON

Cronos Group

$6.78

-0.49 (-6.74%)

CANN

General Cannabis

$0.00

(0.00%)

IGC

India Globalization Capital

$0.81

-0.0228 (-2.74%)

TLRY

Tilray

$19.55

-1.41 (-6.73%)

TCNNF

Trulieve Cannabis

$0.00

(0.00%)

ZYNE

Zynerba

$6.06

-0.35 (-5.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 19

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.